Peritoneal Metastasis: Current Status and Treatment Options

Hemminki, 2016, Patterns of metastasis in colon and rectal cancer, Sci. Rep., 6, 29765, 10.1038/srep29765

Segelman, 2012, Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer, Br. J. Surg., 99, 699, 10.1002/bjs.8679

Sadeghi, 2000, Peritoneal carcinomatosis from non-gynecologic malignancies: Results of the EVOCAPE 1 multicentric prospective study, Cancer, 88, 358, 10.1002/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O

Breuer, E., Hebeisen, M., Schneider, M.A., Roth, L., Pauli, C., Frischer-Ordu, K., Eden, J., Pache, B., Steffen, T., and Hubner, M. (2021). Site of Recurrence and Survival after Surgery for Colorectal Peritoneal Metastasis. J. Natl. Cancer. Inst.

Franko, 2016, Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: An analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database, Lancet. Oncol., 17, 1709, 10.1016/S1470-2045(16)30500-9

Yawar, 2015, Multidetector CT Patterns of Peritoneal Involvement in Patients with Abdominopelvic Malignancies, J. Coll. Physicians. Surg. Pak., 25, 399

Fearon, 1990, A genetic model for colorectal tumorigenesis, Cell, 61, 759, 10.1016/0092-8674(90)90186-I

Pino, 2010, The chromosomal instability pathway in colon cancer, Gastroenterology, 138, 2059, 10.1053/j.gastro.2009.12.065

Karunasena, 2018, Genomics of Peritoneal Malignancies, Surg. Oncol. Clin. N. Am., 27, 463, 10.1016/j.soc.2018.02.004

Guinney, 2015, The consensus molecular subtypes of colorectal cancer, Nat. Med., 21, 1350, 10.1038/nm.3967

Yaeger, 2018, Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer, Cancer Cell, 33, 125, 10.1016/j.ccell.2017.12.004

Schneider, 2018, Mutations of RAS/RAF Proto-oncogenes Impair Survival After Cytoreductive Surgery and HIPEC for Peritoneal Metastasis of Colorectal Origin, Ann. Surg., 268, 845, 10.1097/SLA.0000000000002899

Zajac, 2018, Tumour spheres with inverted polarity drive the formation of peritoneal metastases in patients with hypermethylated colorectal carcinomas, Nat. Cell Biol., 20, 296, 10.1038/s41556-017-0027-6

Lemoine, 2016, Pathophysiology of colorectal peritoneal carcinomatosis: Role of the peritoneum, World J. Gastroenterol., 22, 7692, 10.3748/wjg.v22.i34.7692

Kim, 2018, Establishment and Characterization of Paired Primary and Peritoneal Seeding Human Colorectal Cancer Cell Lines: Identification of Genes That Mediate Metastatic Potential, Transl. Oncol., 11, 1232, 10.1016/j.tranon.2018.07.014

Moffitt, L., Karimnia, N., Stephens, A., and Bilandzic, M. (2019). Therapeutic Targeting of Collective Invasion in Ovarian Cancer. Int. J. Mol. Sci., 20.

Hanahan, 2011, Hallmarks of cancer: The next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013

Hayashi, 2007, Real-time imaging of tumor-cell shedding and trafficking in lymphatic channels, Cancer Res., 67, 8223, 10.1158/0008-5472.CAN-07-1237

Uruski, 2018, The peritoneal “soil” for a cancerous “seed”: A comprehensive review of the pathogenesis of intraperitoneal cancer metastases, Cell Mol. Life Sci., 75, 509, 10.1007/s00018-017-2663-1

Saito, 2013, CD44v6 expression is related to mesenchymal phenotype and poor prognosis in patients with colorectal cancer, Oncol. Rep., 29, 1570, 10.3892/or.2013.2273

Gerber, 2006, Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth, Am. J. Pathol., 169, 1739, 10.2353/ajpath.2006.051222

Heath, 2004, Tumour-induced apoptosis in human mesothelial cells: A mechanism of peritoneal invasion by Fas Ligand/Fas interaction, Br. J. Cancer, 90, 1437, 10.1038/sj.bjc.6601635

Yao, 2019, Role of HGF/c-Met in the treatment of colorectal cancer with liver metastasis, J. Biochem. Mol. Toxicol., 33, e22316, 10.1002/jbt.22316

Said, 2014, The role of matrix metalloproteinases in colorectal cancer, Cancers, 6, 366, 10.3390/cancers6010366

Vocka, 2019, Serum levels of TIMP-1 and MMP-7 as potential biomarkers in patients with metastatic colorectal cancer, Int. J. Biol. Markers, 34, 292, 10.1177/1724600819866202

Varghese, 2007, Site-specific gene expression profiles and novel molecular prognostic factors in patients with lower gastrointestinal adenocarcinoma diffusely metastatic to liver or peritoneum, Ann. Surg. Oncol., 14, 3460, 10.1245/s10434-007-9557-7

Fuchs, 2008, Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: Results from intergroup trial N9741, Clin. Cancer Res., 14, 8263, 10.1158/1078-0432.CCR-08-0480

Dunn, 2004, The three Es of cancer immunoediting, Ann. Rev. Immunol., 22, 329, 10.1146/annurev.immunol.22.012703.104803

Dunn, 2002, Cancer immunoediting: From immunosurveillance to tumor escape, Nat. Immunol., 3, 991, 10.1038/ni1102-991

Chae, 2018, Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC), J. Immunother. Cancer, 6, 39, 10.1186/s40425-018-0349-3

Ogino, 2009, Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype, Clin. Cancer. Res., 15, 6412, 10.1158/1078-0432.CCR-09-1438

Merok, 2013, Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: Results from a large, consecutive Norwegian series, Ann. Oncol., 24, 1274, 10.1093/annonc/mds614

Popat, 2005, Systematic review of microsatellite instability and colorectal cancer prognosis, J. Clin. Oncol., 23, 609, 10.1200/JCO.2005.01.086

Jass, 1998, Morphology of sporadic colorectal cancer with DNA replication errors, Gut, 42, 673, 10.1136/gut.42.5.673

Giannakis, 2016, Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma, Cell Rep., 17, 1206, 10.1016/j.celrep.2016.10.009

Peng, J., Wang, Y., Zhang, R., Deng, Y., Xiao, B., Ou, Q., Sui, Q., Xu, J., Qin, J., and Lin, J. (2019). Immune Cell Infiltration in the Microenvironment of Liver Oligometastasis from Colorectal Cancer: Intratumoural CD8/CD3 Ratio Is a Valuable Prognostic Index for Patients Undergoing Liver Metastasectomy. Cancers, 11.

Seebauer, 2016, Peritoneal carcinomatosis of colorectal cancer is characterized by structural and functional reorganization of the tumor microenvironment inducing senescence and proliferation arrest in cancer cells, Oncoimmunology, 5, e1242543, 10.1080/2162402X.2016.1242543

Wang, 2020, Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response, Gut, 69, 18, 10.1136/gutjnl-2018-318070

Sato, 2005, Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer, Proc. Natl. Acad. Sci. USA, 102, 18538, 10.1073/pnas.0509182102

Auer, 2015, Peritoneal tumor spread in serous ovarian cancer-epithelial mesenchymal status and outcome, Oncotarget, 6, 17261, 10.18632/oncotarget.3746

Auer, 2016, Role of the immune system in the peritoneal tumor spread of high grade serous ovarian cancer, Oncotarget, 7, 61336, 10.18632/oncotarget.11038

Parvathareddy, 2021, Differential expression of PD-L1 between primary and metastatic epithelial ovarian cancer and its clinico-pathological correlation, Sci. Rep., 11, 3750, 10.1038/s41598-021-83276-z

Sugarbaker, 2005, Surgical management of carcinomatosis from colorectal cancer, Clin. Colon Rectal Surg., 18, 190, 10.1055/s-2005-916280

Neuwirth, 2016, Then and now: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), a historical perspective, J. Gastrointest. Oncol., 7, 18

Jayne, 2002, Peritoneal carcinomatosis from colorectal cancer, Br. J. Surg., 89, 1545, 10.1046/j.1365-2168.2002.02274.x

Franko, 2010, Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis, Cancer, 116, 3756, 10.1002/cncr.25116

Munnell, 1968, The changing prognosis and treatment in cancer of the ovary. A report of 235 patients with primary ovarian carcinoma 1952-1961, Am. J. Obstet. Gynecol., 100, 790, 10.1016/S0002-9378(15)33580-8

Munnell, 1969, Surgical treatment of ovarian carcinoma, Clin. Obstet. Gynecol., 12, 980, 10.1097/00003081-196912040-00011

Griffiths, 1979, Role of cytoreductive surgical treatment in the management of advanced ovarian cancer, Cancer Treat Rep., 63, 235

Long, 1969, Pseudomyxoma peritonei. New concepts in management with a report of seventeen patients, Am. J. Surg., 117, 162, 10.1016/0002-9610(69)90300-6

Dedrick, 1978, Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer, Cancer Treat Rep., 62, 1

Sugarbaker, 1995, Peritonectomy procedures, Ann. Surg., 221, 29, 10.1097/00000658-199501000-00004

Jacquet, 1996, Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis, Cancer Treat Res., 82, 359, 10.1007/978-1-4613-1247-5_23

Steffen, 2019, Diagnostic Nodes of Patient Selection for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Among Colorectal Cancer Patients: A Swiss National Multicenter Survey, Clin. Colorectal. Cancer, 18, e335, 10.1016/j.clcc.2019.06.002

Glehen, 2004, Peritoneal carcinomatosis from digestive tract cancer: New management by cytoreductive surgery and intraperitoneal chemohyperthermia, Lancet Oncol., 5, 219, 10.1016/S1470-2045(04)01425-1

Engbersen, 2020, Diagnostic performance of imaging for the detection of peritoneal metastases: A meta-analysis, Eur. Radiol., 30, 3101, 10.1007/s00330-019-06524-x

Passot, 2018, Multicentre study of laparoscopic or open assessment of the peritoneal cancer index (BIG-RENAPE), Br. J. Surg., 105, 663, 10.1002/bjs.10723

Elias, 2009, Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin, J. Clin. Oncol., 27, 681, 10.1200/JCO.2008.19.7160

Quenet, 2021, Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): A multicentre, randomised, open-label, phase 3 trial, Lancet Oncol., 22, 256, 10.1016/S1470-2045(20)30599-4

Verwaal, 2003, Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer, J. Clin. Oncol., 21, 3737, 10.1200/JCO.2003.04.187

Verwaal, 2008, 8-year follow-up of randomized trial: Cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer, Ann. Surg. Oncol., 15, 2426, 10.1245/s10434-008-9966-2

Turaga, 2014, Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States, Ann. Surg. Oncol., 21, 1501, 10.1245/s10434-013-3061-z

Yurttas, C., Hoffmann, G., Tolios, A., Haen, S.P., Schwab, M., Königsrainer, I., Königsrainer, A., Beckert, S., and Löffler, M.W. (2018). Systematic Review of Variations in Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Metastasis from Colorectal Cancer. J. Clin. Med., 7.

Paz, 2012, A new mechanism of action for the anticancer drug mitomycin C: Mechanism-based inhibition of thioredoxin reductase, Chem. Res. Toxicol., 25, 1502, 10.1021/tx3002065

Arjona-Sánchez, A., Barrios, P., Boldo-Roda, E., Camps, B., Carrasco-Campos, J., Concepción Martín, V., García-Fadrique, A., Gutiérrez-Calvo, A., Morales, R., and Ortega-Pérez, G. (2018). HIPECT4: Multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic intra-peritoneal chemotherapy (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced colorectal carcinoma. BMC Cancer, 18.

Schneider, 2017, Major Postoperative Complications Are a Risk Factor for Impaired Survival after CRS/HIPEC, Ann. Surg. Oncol., 24, 2224, 10.1245/s10434-017-5821-7

Grass, 2017, Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis, Br. J. Surg., 104, 669, 10.1002/bjs.10521

Simkens, 2015, Serious Postoperative Complications Affect Early Recurrence After Cytoreductive Surgery and HIPEC for Colorectal Peritoneal Carcinomatosis, Ann. Surg. Oncol., 22, 2656, 10.1245/s10434-014-4297-y

Virzi, 2013, Pilot study of adjuvant hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer at high risk for the development of peritoneal metastases, Tumori, 99, 589, 10.1177/030089161309900505

Klaver, 2019, Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): A multicentre, open-label, randomised trial, Lancet Gastroenterol. Hepatol., 4, 761, 10.1016/S2468-1253(19)30239-0

Gustavsson, 2015, A review of the evolution of systemic chemotherapy in the management of colorectal cancer, Clin. Colorectal. Cancer, 14, 1, 10.1016/j.clcc.2014.11.002

Loupakis, 2014, Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer, N. Engl. J. Med., 371, 1609, 10.1056/NEJMoa1403108

Falcone, 2007, Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest, J. Clin. Oncol., 25, 1670, 10.1200/JCO.2006.09.0928

Cremolini, 2020, Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): A multicentre, open-label, phase 3, randomised, controlled trial, Lancet Oncol., 21, 497, 10.1016/S1470-2045(19)30862-9

Passot, 2012, Progression following neoadjuvant systemic chemotherapy may not be a contraindication to a curative approach for colorectal carcinomatosis, Ann. Surg., 256, 125, 10.1097/SLA.0b013e318255486a

Demtroder, 2016, Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis, Colorectal. Dis., 18, 364, 10.1111/codi.13130

Goere, 2020, Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): A randomised, phase 3 study, Lancet Oncol., 21, 1147, 10.1016/S1470-2045(20)30322-3

Solass, 2014, Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: First evidence for efficacy, Ann. Surg. Oncol., 21, 553, 10.1245/s10434-013-3213-1

Hollandsworth, 2021, A review of tumor-specific fluorescence-guided surgery for colorectal cancer, Surg. Oncol., 36, 84, 10.1016/j.suronc.2020.11.018

Shariati, M., Willaert, W., Ceelen, W., De Smedt, S.C., and Remaut, K. (2019). Aerosolization of Nanotherapeutics as a Newly Emerging Treatment Regimen for Peritoneal Carcinomatosis. Cancers, 11.

Luo, 2020, Intraperitoneal administration of biocompatible hyaluronic acid hydrogel containing multi-chemotherapeutic agents for treatment of colorectal peritoneal carcinomatosis, Int J. Biol. Macromol., 152, 718, 10.1016/j.ijbiomac.2020.02.326

Zhang, 2021, Neoadjuvant Intraperitoneal and Systemic Chemotherapy Versus Neoadjuvant Systemic Chemotherapy with Docetaxel, Oxaliplatin, and S-1 for Gastric Cancer with Peritoneal Metastasis: A Propensity Score Matched Analysis, Technol. Cancer Res. Treat., 20, 15330338211036310, 10.1177/15330338211036310

Overman, 2018, Durable Clinical Benefit with Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer, J. Clin. Oncol., 36, 773, 10.1200/JCO.2017.76.9901

Shiu, 2020, Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer, N. Engl. J. Med., 383, 2207, 10.1056/NEJMoa2017699

Matulonis, 2019, Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study, Ann. Oncol., 30, 1080, 10.1093/annonc/mdz135

Tesniere, 2010, Immunogenic death of colon cancer cells treated with oxaliplatin, Oncogene, 29, 482, 10.1038/onc.2009.356

Green, 2009, Immunogenic and tolerogenic cell death, Nat. Rev. Immunol., 9, 353, 10.1038/nri2545

Sharma, A., Bode, B., Wenger, R.H., Lehmann, K., Sartori, A.A., Moch, H., Knuth, A., Boehmer, L., and Broek, M. (2011). gamma-Radiation promotes immunological recognition of cancer cells through increased expression of cancer-testis antigens in vitro and in vivo. PLoS ONE, 6.

Zunino, 2016, Hyperthermic intraperitoneal chemotherapy leads to an anticancer immune response via exposure of cell surface heat shock protein 90, Oncogene, 35, 261, 10.1038/onc.2015.82

Froysnes, 2017, Novel Treatment with Intraperitoneal MOC31PE Immunotoxin in Colorectal Peritoneal Metastasis: Results From the ImmunoPeCa Phase 1 Trial, Ann. Surg. Oncol., 24, 1916, 10.1245/s10434-017-5814-6